抗血管内皮生长因子治疗湿性年龄相关性黄斑变性

Anti-vascular endothelial growth factor for wet age-related macular degeneration

年龄相关性黄斑变性(AMD)可分为干性(非渗出性)或湿性(渗出性或新生血管性)2种类型。湿性AMD的主要特征是脉络膜新生血管(CNV)生成,CNV可发生渗出和出血,已成为我国及欧美发达国家年龄在50岁以上人群视力严重下降甚至丧失的主要原因。抗血管内皮生长因子(VEGF)玻璃体腔注射是目前治疗湿性AMD的首选药物,大量临床研究显示较好的治疗效果来自于有较好基线视力的患者,早诊断、早治疗及规范化治疗是保证治疗效果的重要因素。

Age-related macular degeneration （AMD） is classified as dry （non-exudative） and wet （exudative） type. Wet AMD is characterized by choroidal neovascularization （CNV） which contributes to exudates and aemorrhage. Now wet AMD has become the leading cause of severe vision loss in populations over 50 year-old not only Ln developed countries but also in our country. Vitreal injection of anti-vascular endothelial growth factor is considered ：he mainstay for wet AMD and the clinical trials has proved that the best benefit wet AMD patients are those who accept ：he therapy at a better baseline vision. Therefore early diagnosis and standardized practical principle therapy are recommended for wet AMD patients.